Publication

Population Pharmacokinetics of Tranexamic Acid in Chinese Population Undergoing Cardiac Surgery with Cardiopulmonary Bypass

Discover how the First Chinese TXA PopPK model shows body weight drives TXA disposition and…

CertaraMay 26, 2025

On-Demand Webinar

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

We explore the evolving regulatory landscape for Model-Informed Drug Development (MIDD), focusing on the impact…

CertaraMay 23, 2025

Blog

CERTAINTY 2025: The power of model-informed drug development

We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…

CertaraMay 16, 2025

On-Demand Webinar

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Learn how a stepwise C-QTc approach can streamline cardiac safety evaluation, reduce costs, and align…

CertaraMay 5, 2025

Fact Sheet

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Certara’s Non-Animal Navigator™ solution helps companies adapt by selecting and optimizing the best-fit NAM strategies.

CertaraApril 30, 2025

Publication

Comparative pharmacokinetics and bioequivalence of 145-mg fenofibrate formulations in healthy Korean participants

See how new fenofibrate formulation meets bioequivalence criteria and shows comparable safety in a crossover…

CertaraApril 30, 2025

Announcement

Certara Announces Second Annual Certainty U.S. Event

Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…

CertaraApril 22, 2025

Press Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…

CertaraApril 14, 2025

Publication

Enhanced Absorption and Safety of MuscleBlaze CreAMP™: A Comparative Analysis With Regular Micronized Creatine Monohydrate in Healthy Male Adults

Learn how CreAMP shows higher bioavailability, longer half‑life, and lower clearance than standard creatine, analysed…

CertaraApril 1, 2025

Publication

The effect of high-fat diet on the pharmacokinetics of ondansetron hydrochloride tablets in healthy Chinese subjects

Find out how high‑fat meals significantly reduce ondansetron exposure, falling outside bioequivalence bounds, analysed using…

CertaraMarch 21, 2025

Modeling and Simulation

Population Pharmacokinetics of Tranexamic Acid in Chinese Population Undergoing Cardiac Surgery with Cardiopulmonary Bypass

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

CERTAINTY 2025: The power of model-informed drug development

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Comparative pharmacokinetics and bioequivalence of 145-mg fenofibrate formulations in healthy Korean participants

Certara Announces Second Annual Certainty U.S. Event

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Enhanced Absorption and Safety of MuscleBlaze CreAMP™: A Comparative Analysis With Regular Micronized Creatine Monohydrate in Healthy Male Adults

The effect of high-fat diet on the pharmacokinetics of ondansetron hydrochloride tablets in healthy Chinese subjects

Newsletter sign up

Quick links

Solutions

Contact